Literature DB >> 16735397

Multimodal evoked potentials to assess the evolution of multiple sclerosis: a longitudinal study.

L Leocani1, M Rovaris, F M Boneschi, S Medaglini, P Rossi, V Martinelli, S Amadio, G Comi.   

Abstract

BACKGROUND: Evoked potentials are used in the functional assessment of sensory and motor pathways. Their usefulness in monitoring the evolution of multiple sclerosis has not been fully clarified.
OBJECTIVE: The aim of this longitudinal study was to examine the usefulness of multimodal evoked potential in predicting paraclinical outcomes of disease severity and as a prognostic marker in multiple sclerosis.
METHODS: Eighty four patients with clinically definite multiple sclerosis underwent Expanded Disability Status Scale (EDSS) and functional system scoring at study entry and after a mean (standard deviation) follow-up of 30.5 (11.7) months. Sensory and motor evoked potentials were obtained in all patients at study entry and at follow-up in 64 of them, and quantified according to a conventional score.
RESULTS: Cross-sectionally, the severity of each evoked potential score significantly correlated with the corresponding functional system (0.32 < R < 0.60, p < 0.01, for all but follow-up visual evoked potential) and with EDSS (0.34 < R < 0.61; p < 0.001 for all but brain stem evoked potential). EDSS significantly correlated with global evoked potential score severity (baseline R = 0.60, follow-up R = 0.46, p < 0.001). Using longitudinal analysis, only changes in somatosensory evoked potential scores were significantly correlated with changes of sensory functional system (R = 0.34, p = 0.006). However, patients with multiple sclerosis with disability progression at follow-up had more severe baseline evoked potential scores than patients who remained stable. Patients with severe baseline global evoked potential score (higher than the median value) had a risk of 72.5% to progress on disability at follow-up, whereas patients with multiple sclerosis with lower scores had a risk of only 36.3%.
CONCLUSIONS: These results suggest that evoked potential is a good marker of the severity of nervous damage in multiple sclerosis and may have a predictive value regarding the evolution of disability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16735397      PMCID: PMC2077734          DOI: 10.1136/jnnp.2005.086280

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  36 in total

Review 1.  Can evoked potentials be useful in monitoring multiple sclerosis evolution?

Authors:  G Comi; T Locatelli; L Leocani; S Medaglini; P Rossi; V Martinelli
Journal:  Electroencephalogr Clin Neurophysiol Suppl       Date:  1999

2.  Recommendations for the practice of clinical neurophysiology: guidelines of the International Federation of Clinical Neurophysiology.

Authors: 
Journal:  Electroencephalogr Clin Neurophysiol Suppl       Date:  1999

Review 3.  The diagnosis and management of multiple sclerosis.

Authors:  C M Poser
Journal:  Acta Neurol Scand       Date:  2005-09       Impact factor: 3.209

4.  Evoked potential abnormality scores are a useful measure of disease burden in relapsing-remitting multiple sclerosis.

Authors:  P O'Connor; P Marchetti; L Lee; M Perera
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

5.  Evoked potentials predict the clinical changes in a multiple sclerosis drug study.

Authors:  M R Nuwer; J W Packwood; L W Myers; G W Ellison
Journal:  Neurology       Date:  1987-11       Impact factor: 9.910

6.  Serial evoked potential studies and MRI imaging in chronic progressive multiple sclerosis.

Authors:  R A Sater; A M Rostami; S Galetta; R E Farber; S J Bird
Journal:  J Neurol Sci       Date:  1999-12-15       Impact factor: 3.181

7.  Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.

Authors:  F D Lublin; S C Reingold
Journal:  Neurology       Date:  1996-04       Impact factor: 9.910

8.  Sensory impairments in spinal multiple sclerosis: a combined clinical, magnetic resonance imaging and somatosensory evoked potential study.

Authors:  T Fukutake; S Kuwabara; M Kaneko; S Kojima; T Hattori
Journal:  Clin Neurol Neurosurg       Date:  1998-09       Impact factor: 1.876

9.  Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

10.  Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis.

Authors:  M Filippi; A Campi; S Mammi; V Martinelli; T Locatelli; G Scotti; S Amadio; N Canal; G Comi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-01       Impact factor: 10.154

View more
  26 in total

1.  Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study).

Authors:  O Fernández; V Fernández; T Arbizu; G Izquierdo; I Bosca; R Arroyo; J A García Merino; E de Ramón
Journal:  J Neurol       Date:  2010-04-10       Impact factor: 4.849

Review 2.  Neurophysiological markers.

Authors:  Letizia Leocani; Giancarlo Comi
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

3.  Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score.

Authors:  Paolo Invernizzi; Laura Bertolasi; Maria Rachele Bianchi; Marco Turatti; Alberto Gajofatto; Maria Donata Benedetti
Journal:  J Neurol       Date:  2011-04-09       Impact factor: 4.849

4.  Comparison of brainstem reflex recordings and evoked potentials with clinical and MRI data to assess brainstem dysfunction in multiple sclerosis: a short-term follow-up.

Authors:  I Magnano; G M Pes; M P Cabboi; G Pilurzi; F Ginatempo; A Achene; A Salis; M Conti; Franca Deriu
Journal:  Neurol Sci       Date:  2016-05-13       Impact factor: 3.307

5.  Psychophysiological and electrophysiological testing of olfactory and gustatory function in patients with multiple sclerosis.

Authors:  Sarah Bettina Dahlslett; Oender Goektas; Felix Schmidt; Lutz Harms; Heidi Olze; Franca Fleiner
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-11-06       Impact factor: 2.503

6.  Sensory evoked potentials to predict short-term progression of disability in multiple sclerosis.

Authors:  N Margaritella; L Mendozzi; M Garegnani; E Colicino; E Gilardi; L Deleonardis; F Tronci; L Pugnetti
Journal:  Neurol Sci       Date:  2011-11-27       Impact factor: 3.307

7.  Computational classifiers for predicting the short-term course of Multiple sclerosis.

Authors:  Bartolome Bejarano; Mariangela Bianco; Dolores Gonzalez-Moron; Jorge Sepulcre; Joaquin Goñi; Juan Arcocha; Oscar Soto; Ubaldo Del Carro; Giancarlo Comi; Letizia Leocani; Pablo Villoslada
Journal:  BMC Neurol       Date:  2011-06-07       Impact factor: 2.474

8.  Exploring the predictive value of the evoked potentials score in MS within an appropriate patient population: a hint for an early identification of benign MS?

Authors:  Nicolò Margaritella; Laura Mendozzi; Massimo Garegnani; Raffaello Nemni; Elena Colicino; Elisabetta Gilardi; Luigi Pugnetti
Journal:  BMC Neurol       Date:  2012-08-22       Impact factor: 2.474

9.  Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II).

Authors:  Claire M Rice; David I Marks; Peter Walsh; Nick M Kane; Martin G Guttridge; Juliana Redondo; Pamela Sarkar; Denise Owen; Alastair Wilkins; Neil J Scolding
Journal:  BMJ Open       Date:  2015-09-11       Impact factor: 2.692

Review 10.  Clinical, MRI, and CSF markers of disability progression in multiple sclerosis.

Authors:  Alberto Gajofatto; Massimiliano Calabrese; Maria Donata Benedetti; Salvatore Monaco
Journal:  Dis Markers       Date:  2013-11-10       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.